Stryker (NYSE:SYK) Stock Rating Lowered by Wall Street Zen

by · The Markets Daily

Stryker (NYSE:SYK – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts also recently issued research reports about the stock. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Rothschild Redb upgraded Stryker to a “hold” rating in a report on Thursday, September 18th. Evercore ISI reduced their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Wells Fargo & Company boosted their target price on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 price target on shares of Stryker in a research note on Friday, November 14th. Twelve analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $431.83.

Check Out Our Latest Stock Report on SYK

Stryker Stock Performance

NYSE SYK opened at $353.99 on Friday. The business’s 50 day moving average price is $366.81 and its 200-day moving average price is $378.45. Stryker has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a market cap of $135.37 billion, a P/E ratio of 46.52, a P/E/G ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts predict that Stryker will post 13.47 earnings per share for the current year.

Insider Activity

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 522,118 shares of company stock worth $185,381,932. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Stryker in the 2nd quarter worth approximately $26,000. Clayton Financial Group LLC purchased a new position in Stryker in the third quarter worth $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the third quarter worth $27,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $28,000. Finally, Sachetta LLC grew its stake in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

(Get Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Stories